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Table 1
Patient Characteristics
Characteristic/Outcome t(4;14),
N¼23 (%)
Control,
N¼92 (%)
P
Median follow-up, months (range) 41 (18-46) 23 (1-76)
Median age, years (range) 59 (40-72) 59 (31-79)
60 12 (52) 48 (52)
>60 11(48) 44 (48) .99
Diagnosis to auto-HCT (%)
1 year 18 (78) 35 (38)
>1 year 5(22) 57 (62) .1
ISS stage (%)
I 3(13) 30 (33)
II 4(17) 19 (21)
III 12 (52) 15 (16)
Unknown 4(17) 28 (30) .04
Disease status (%)
Relapse 12 (52) 28 (30)
Other 11 (48) 64 (70) .05
Prior auto-HCT
Yes 0(0) 13 (14)
No 23(100) 79 (86) .05
Response prior to Auto-HCT (%)
CR/nCR/sCR 0(0) 18 (19)
VGPR 9 (39) 17 (18)
PR 10 (43) 41 (45)
SD 1(4) 10 (11)
PD 3(13) 6 (7) .6
Preparative regimen (%)
Melphalan alone 19 (83) 66 (72)
Melphalan + other 4(17) 25 (27) .3
.04
PI before auto-HCT 22 (91) 70 (76)
IMiD before auto-HCT 13 (57) 48 (52) .71
A capillary found in the lamina propria of esophagus from patient with TMA
(H&E 400x). There is ﬁbrin deposit (microthrombus) present in the space
between the basement membrane and separated endothelial cells ( * ) The
endothelial cells appear degenerated ( Y ) Fragmented red blood cells are in
the lumen.
MAC Myaloablative Conditioning: TBI 200cGy. Clofarabine 52 mg/m2
5days; AraC 1 gm/m2/d  6 days RTC: Reduced Toxicity Conditioning:
Bmulfan 4 mg/kg/d  4 days; Fludarabine 30 mg/m2/ d5 days; Alemtu-
zumab 2 mg/m21 days, 6 mg/m2 2 days
Figure 2. OS
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emerged as adverse prognostic factors.
Conclusion: Patients with t(4;14) have a signiﬁcantly shorter
PFS and OS even after an auto-SCT. Use of novel approaches
like post-transplant consolidation, maintenance, and im-
mune-based therapies should be explored in these high-risk
patients.Figure 1. PFS268
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Abstracts / Biol Blood Marrow Transplant 21 (2015) S185eS205S204Background: Gain of chromosome 1q (+1q) is a frequent
abnormality that has been associated with resistance to
treatment and shorter survival in MM. We describe the
impact of autologous transplantation (auto) on survival
after treatment with novel agent based induction
regimens.
Methods: We identiﬁed 135 newly diagnosed symptomatic
MM patients who had FISH performed on pre-treatment
bone marrow specimens at our institution between 1/2009
and 12/2012. Standard karyotype and FISH were performed
as previously described (Gerritsen et al. Blood 1992), and
the copy number and percentage of cells involved was
collected. Progression free survival (PFS) and overall survivalFigure 3.(OS) were calculated based on IMWG criteria from diagnosis
and transplant and estimated by Kaplan-Meier A log-rank
test was used to compare survival based on +1q, and Cox
proportional-hazards regression was used to further adjust
for standard MM risk factors.
Results: 25/135 (19%) had +1q. Median age was 60 with the
majority of patients being male (76% in with+1q vs 57%
without, p¼0.112) and Caucasian (76 vs 73%). Median
follow-up was 3.2 years (yrs) (range 0.13-5.5). When
compared to patients without +1q, 40 vs 49% had Interna-
tional Staging System (ISS) Stage I disease, while 28 vs 25%
had Stage II, and 32 vs 26% had Stage III (p¼0.63). Complex
karyotype was seen in 52% with +1q vs 15% without
(p¼0.002). 64 vs 43% (p¼0.075) had extramedullary disease
and 96 vs 78% (p¼0.045) had lytic lesions at diagnosis. Copy
number of +1q ranged from 3-5 with a median of 17% of
cells involved (range 2-98%). Induction regimens included
combination lenalidomide(R), bortezomib (V), cyclophos-
phamide (C), & dexamethasone (D), with 31% receiving RD,
12% VD, 30% RVD, and 16% VCD. Best response to induction
was >very good partial response in 40 vs 54% (p¼0.27). 80
vs 68% underwent auto, and 32 vs 5% both auto and allo.
Median PFS was 2.13 years (1.71- not reached (NR)) with
+1q vs 3.87 years (3.21- NR) without (Figure 1), while
median OS was 4.4 years (2.93-NR) with +1q and was not
reached in those without (Figure 2). After an auto, median
PFS and OS were lower with +1q (p¼0.006, p¼0.006)
(Figure 3). On univariate and multivariate analysis, +1q
and ISS stage were signiﬁcantly associated with worse PFS.
For OS, both ISS and +1q were signiﬁcant on univariate,
but only ISS on multivariate analysis.
Conclusion: Patients were more likely to have complex
karyotypes and lytic lesions at diagnosis. Response to novel
agent induction regimens was high and similar in both
groups. Overall, gain of 1q portends worse PFS and OS which
is not negated by auto transplant.
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Introduction: Diffuse large B-cell lymphoma (DLBCL) is the
most frequent lymphoma in the adult population, repre-
senting 25-35% of new non-Hodgkin lymphoma cases each
year (Cultrera & Dalia, 2012). Autologous hematopoietic
stem cell transplant (HSCT) is the standard of care after
relapse following conventional treatment, with a curative
potential of 25-50%, but recurrences are common. Alloge-
neic HSCT represents a salvage option through the beneﬁt
of graft-versus-lymphoma effect. The role of allogeneic
HSCT in patients with advanced DLBCL still remains to be
deﬁned. In this analysis we evaluated the outcomes of
allogeneic HSCT in a group of patients with advanced, high
